<< Back

Richard S. Kollender
Richard has served as a member of our board of directors since March 2015. He currently serves as chief business officer, chief financial officer and as a member of the board of directors of Rapid Micro BioSystems. Since 2005, he has served as a partner of Quaker Partners Management, LP, a healthcare investment firm, which he initially joined in 2003. Richard is also on the board of directors of Tarsa Therapeutics. Richard also serves on the public policy committee for Pennsylvania Bio and is an adjunct faculty member at Lehigh University. He previously served on the board of directors of Insmed; Transave, Inc.; Nupathe, Inc.; TargetRx, Inc.; Precision Therapeutics, Inc.; Transport Pharmaceuticals, Inc.; Corridor Pharmaceuticals; Celator Pharmaceuticals; and PACT (Greater Philadelphia Alliance for Capital and Technologies). Richard has held positions in sales, marketing and worldwide business development at GlaxoSmithKline and served as investment manager at S.R. One. He practiced as a certified public accountant for 6 years at public accounting firms, including KPMG.

Richard holds an MBA with honors and a Certificate Degree in the Graduate Program in Health Administration and Policy from University of Chicago and a BA in accounting from Franklin and Marshall College.
Financial Expert

© 2018 Strongbridge Biopharma plc
STRONGBRIDGE BIOPHARMA® is a registered trademark of the Strongbridge Biopharma plc. companies, which include Strongbridge Ireland Limited and Strongbridge U.S. Inc.
KEVEYIS® is a registered trademark licensed exclusively in the U.S. to Strongbridge Biopharma plc.
Macrilen is a trademark of Aeterna Zentaris GmbH, licensed exclusively in the U.S. and Canada to Strongbridge Ireland Limited.
MLR-0010 V13 01/2018

900 Northbrook Drive, Suite 200
Trevose, PA 19053
United States
Phone: +1 610-254-9200
[email protected]

Privacy Statement
Compliance Program